Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: Systematic review and meta-analysis

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 6, 2012, Pages 746-756

  Danese, E ^a   Montagnana, M ^a   Johnson, J A ^b   Rettie, A E ^c   Zambon, C F ^d   Lubitz, S A ^e   Suarez Kurtz, G ^f   Cavallari, L H ^g   Zhao, L ^h   Huang, M ^h   Nakamura, Y ⁱ   Mushiroda, T ^j   Kringen, M K ^k   Borgiani, P ^l   Ciccacci, C ^l   Au, N T ^c   Langaee, T ^b   Siguret, V ^m   Loriot, M A ^m   Sagreiya, H ^n,o   Altman, R B ^n,o   Shahin, M H A ^b   Scott, S A ^p   Khalifa, S I ^q   Chowbay, B ^r   Suriapranata, I M ^s   Teichert, M ^t   Stricker, B H ^t   Taljaard, M ^u   Botton, M R ^v   Zhang, J E ^x   Pirmohamed, M ^w   Zhang, X ^x   Carlquist, J F ^y   Horne, B D ^y   Lee, M T M ^z   Pengo, V ^d   Guidi, G C ^a   Minuz, P ^a   Fava, C ^a,aa   more..

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h SUN YAT SEN UNIVERSITY   (China)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j RIKEN   (Japan)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ Stanford University ^*  (United States)

^o STANFORD UNIVERSITY   (United States)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^q Qatar University   (Qatar)

^r DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^s PELITA HARAPAN UNIVERSITY   (Indonesia)

^t ERASMUS MEDICAL CENTER   (Netherlands)

^u OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^v FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^w UNIVERSITY OF LIVERPOOL   (United Kingdom)

^x WADSWORTH CENTER   (United States)

^y UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^z INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^aa LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; CYTOCHROME P450 ISOENZYME; MENADIONE EPOXIDE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ARTICLE; DEEP VEIN THROMBOSIS; ENZYME SUBUNIT; ETHNICITY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; PHARMACOGENETICS; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALLELES; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; COUMARINS; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; PUBLICATION BIAS; SEX FACTORS;

EID: 84869497712     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.184     Document Type: Article

References (50)

1. Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. & Hylek, E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 204S-233S (2004). (Pubitemid 39297955)
2. Budnitz, D.S., Lovegrove, M.C., Shehab, N. & Richards, C.L. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365, 2002-2012 (2011).
3. Lurie, Y., Loebstein, R., Kurnik, D., Almog, S. & Halkin, H. Warfarin and vitamin K intake in the era of pharmacogenetics. Br. J. Clin. Pharmacol. 70, 164-170 (2010).
4. Cavallari, L.H., Shin, J. & Perera, M.A. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31, 1192-1207 (2011).
5. McDonald, M.G., Rieder, M.J., Nakano, M., Hsia, C.K. & Rettie, A.E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75, 1337-1346 (2009).
6. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
7. Fava, C. et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52, 373-380 (2008).
8. Fava, C., Ricci, M., Melander, O. & Minuz, P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation? Prostaglandins Other Lipid Mediat. 98, 75-85 (2012).
9. Cavallari, L.H. et al. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy 31, 785-792 (2011).
10. Chan, S.L. et al. Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population. Thromb. Haemost. 105, 1100-1102 (2011).
11. Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
12. Ashley, E.A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
13. Ciccacci, C. et al. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet. Genomics 21, 344-346 (2011).
14. Isaza, C. et al. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients]. Biomedica. 30, 410-420 (2010).
15. Borgiani, P. et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10, 261-266 (2009).
16. Botton, M.R., Bandinelli, E., Rohde, L.E., Amon, L.C. & Hutz, M.H. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br. J. Clin. Pharmacol. 72, 442-450 (2011).
17. Carlquist, J.F. et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J. Thromb. Thrombolysis 30, 358-364 (2010).
18. Cavallari, L.H. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87, 459-464 (2010).
19. Cen, H.J. et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br. J. Clin. Pharmacol. 70, 234-240 (2010).
20. Cha, P.C. et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19, 4735-4744 (2010).
21. Chan, S.L., Suo, C., Lee, S.C., Goh, B.C., Chia, K.S. & Teo, Y.Y. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J. 12, 312-318 (2012).
22. Choi, J.R. et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J. Hum. Genet. 56, 290-295 (2011).
23. Gong, I.Y. et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS ONE 6, e27808 (2011).
24. Harada, T. et al. Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb. Res. 126, 183-190 (2010).
25. Kringen, M.K. et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J. Biomed. Biotechnol. 2011, 739751 (2011).
26. Lee, M.T. et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10, 1905-1913 (2009).
27. Lubitz, S.A. et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 8, 1018-1026 (2010).
28. Pautas, E. et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87, 57-64 (2010).
29. Perini, J.A., Struchiner, C.J., Silva-Assunção, E. & Suarez-Kurtz, G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Ther. 87, 417-420 (2010).
30. Sagreiya, H. et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genomics 20, 407-413 (2010).
31. Shahin, M.H. et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet. Genomics 21, 130-135 (2011).
32. Singh, O., Sandanaraj, E., Subramanian, K., Lee, L.H. & Chowbay, B. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab. Pharmacokinet. 26, 130-136 (2011).
33. Suriapranata, I.M. et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med. Genet. 12, 80 (2011).
34. Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
35. Wells, P.S. et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb. Res. 125, e259-e264 (2010).
36. Zambon, C.F. et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12, 15-25 (2011).
37. Zhang, J.E. et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics 19, 781-789 (2009).
38. Zhang, X., Li, L., Ding, X. & Kaminsky, L.S. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39, 1433-1439 (2011).
39. Pérez-Andreu, V. et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113, 4977-4979 (2009).
40. Teichert, M. et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18, 3758-3768 (2009).
41. Geisen, C. et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur. J. Clin. Pharmacol. 67, 371-381 (2011).
42. Teichert, M. et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet. Genomics 21, 26-34 (2011).
43. Liang, R., Wang, C., Zhao, H., Huang, J., Hu, D. & Sun, Y. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and metaanalysis. Thromb. Res. 130, 38-44 (2012).
44. Lindh, J.D., Holm, L., Andersson, M.L. & Rane, A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375 (2009).
45. Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
46. French, B. et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
47. van Schie, R.M. et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
48. Anderson, J.L. et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125, 1997-2005 (2012).
49. Yang, L., Ge, W., Yu, F. & Zhu, H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb. Res. 125, e159-e166 (2010).
50. Stec, D.E., Roman, R.J., Flasch, A. & Rieder, M.J. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics 30, 74-81 (2007). (Pubitemid 47173292)